Good MorningThe equities market got another shot of anti-viral medication on Thursday when Jerome Powell announced major changes in how the Federal Reserve views inflation. Instead of taking inflation at face value, the committee will use an average-inflation approach in an effort to help sustain economic growth. Under the new policy, inflation could run well above the 2.0% target before any policy action or business-stifling rate increases would be taken.
The Fed changes are intended to sustain and accelerate economic growth in the U.S. and the markets responded favorably. The Dow Jones Industrial Average led the days advance with a gain near 1.0% to set a new high for 2020. The S&P 500 and NASDAQ Composite posted smaller advances but both set new highs as well. Investors should expect to see more new highs so long as the data remains favorable.
Featured: Forget the million-dollar nest egg (Ad) 
|
Communication Services | |
The superhero streaming wars is heating up between Walt Disney’s (NYSE: DIS) Marvel Cinematic Universe (MCU) versus AT&T’s Warnermedia’s (NYSE: T) DC Extended Universe (DCEU). For those not familiar with superhero universes, Marvel Studios broke the mold along with all box of... Read the Full Story |
|
From Our Partners | | In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the stock climbed 12,107 percent.
He called streaming video over Blockbuster in 1990 and flagged an obscure online bookshop named Amazon in 1996. Netflix rose 118,823 percent at its peak; Amazon is up 250,300 percent counting splits.
Gilder now points to three converging technologies he calls the Trillion Dollar Triangle, which he believes could outweigh those past breakthroughs combined. | | See the Trillion Dollar Triangle George Gilder is pointing at now |
|
Consumer Discretionary | |
Sometimes, it’s easy to overcomplicate things when it comes to investing. The truth is that many of the best investments begin with a simple thesis that anyone could understand. For example, buying shares of a company that operates a growing e-commerce business in the country with the larges... Read the Full Story |
|
Consumer Discretionary | |
It’s always good to find a bargain. And it’s especially good to make a dollar stretch further in uncertain economic times like these. That formula is working for Ollie’s Bargain Outlet (NASDAQ:OLLI). And investors will find out how well the discount chain is doing when they repor... Read the Full Story |
|
From Our Partners | | President Trump says America is building wealth again, and the U.S. Treasury calls the economy under his administration strong.
But markets still fluctuate, companies still miss expectations, and a major loss late in your career can be harder to recover from than one at age 40.
Physical gold offers protection that does not depend on market momentum, corporate earnings, or consumer spending. | | Download the free 2026 Wealth Preservation Guide to protect your retirement savings |
|
Technology | |
It might be hard to reconcile how a large number of analysts are expecting a stock's price to fall, substantially, yet at the same time be worth buying, but sometimes, that's exactly the case. That's just what's going on with Qorvo (NASDAQ:QRVO), which is turning in big expectations in pretty much... Read the Full Story |
|
Consumer Staples | | One sector that has been a big winner throughout the novel coronavirus pandemic has been the discount retail sector. The discount retail sector is a $95 billion sector. Names like Walmart (NYSE:WMT) and Target (NYSE:TGT) are among the first to come to mind when consumers think low prices. But they a... Read the Full Story |
|
From Our Partners | | Vincere licenses institutional-grade futures algorithms directly to individual investors — no nine-figure minimums, no PhD team required.
Your capital never leaves your U.S.-regulated brokerage or IRA. No leverage, no overnight positions, and the worst month in six years was -2.58 percent. No management fees or profit cuts — every dollar earned stays in your account.
Built by former hedge-fund quant researchers, Chicago-based and SEC-compliant, with a public team you can verify. | | See how the algorithm works inside your own brokerage account |
|
Markets | |
Hormel Is A Post-Pandemic Winner And Highly Valued
There are many reasons why Hormel Foods (NYSE:HRL) stock has done so well during the pandemic. To start, the company is a blue-chip consumer staple with a long history of steady, even returns. In times of trouble, those kinds of stocks are among ... Read the Full Story |
|
Consumer Discretionary | | Outdoor travel and camping retailer Camping World Holdings, Inc. (NYSE: CWH) shares have been on a rollercoaster ride after sinking to lows of $3.40 during the pandemic panic selling that shaved the benchmark S&P 500 index (NYSEARCA: SPY) by (-34%) in the five weeks ending March 24th. However, s... Read the Full Story |
|
Markets | | The healthcare industry sees trillions of dollars spent annually by people around the globe and continues to grow at a rapid pace. With so many people in need of companies that provide healthcare services, investing in stocks that play a key role in the healthcare system could certainly pay off in a... Read the Full Story |
|
Markets | | Some of the biggest moves in the market happen on earnings releases. But growth isn’t always enough to send shares higher. Even beating consensus estimates is sometimes not enough to boost the stock price.
The key is expectations – particularly, the “whisper numbers.” The wh... Read the Full Story |
|
Markets | |
At a quick glance, there’s not a lot to like about Children’s Place (NYSE:PLCE) stock. The company had to shutter its brick-and-mortar operations in response to the Covid-19 pandemic. And the stock is down nearly 200% for the year. Recent analyst ratings have not helped the business ca... Read the Full Story |
|
The Early Bird Stock Of The Day Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. | | View Today's Stock Pick |
|
